Background
==========

Good mental health research is critical to guide healthcare professionals to make informed decisions about the effects of most interventions. Early examples do exist of attempts at fair evaluation of healthcare, including several from Italy \[[@B1],[@B2]\]. However, in 1948 the UK MRC Streptomycin randomized trial was published and remains a landmark of modern healthcare evaluation \[[@B3]\]. After that many specialties began to adopt randomization for the evaluation of treatments.

Mental health has a strong tradition of using trials \[[@B4]\], but translation of research to clinical practice is not always easy. For patients, carers, and policymakers, local data are important. Even well-conducted trials, if undertaken in a very dissimilar care-culture may be difficult to apply. Local trials are important and informative whether they concur - or contradict - other similar studies from afar. The totality of evidence must be considered but the local perspective not ignored. Not to have local studies leaves all interested in the effects of care vulnerable to importing data of limited applicability. Some nations, however, have produced few trials. For schizophrenia trials, measures of national wealth and not public health burden loosely predict the research activity of a country \[[@B5]\]. Italy, however, is the 10th most wealthy nation in terms of GDP <http://www.nationmaster.com/graph/eco_gdp-economy-gdp>.

The quality of mental health research, and trials in particular, may also vary across nations \[[@B4]\]. For example, the volume and quality of trial research from China has been considered in many surveys and quality remains a major concern \[[@B6]-[@B10]\]. Elsewhere it has been shown that pioneering mental health trials from low and middle income countries are of as mixed quality as their more accessible counterparts from richer nations but cannot be identified in commonly used bibliographic databases \[[@B11]\]. Nearer home, in Europe, Romania\'s mental health research has been the focus of recent investigation and the increasing dominance of pharmaceutical industry noted \[[@B12]\].

The Cochrane Schizophrenia Group produces and maintains a register of all studies <http://szg.cochrane.org/cochrane-schizophrenia-group-specialised-register>. This involves regular and systematic searching of 71 databases. The studies identified in this way are reliably indexed by country. The aim of this study is to use part of this dataset to quantify trialing activity in one area of mental healthcare over time in Italy and describe characteristics of these trials. Specifically, we evaluated content and risk of bias of Italian trials relevant to people with schizophrenia from 1948 until 2009 for three key methodological aspects: sample size, duration, and number of outcomes.

Methods
=======

Source
------

We searched the Cochrane Schizophrenia Group Register without time limitation. The search was made in May 2011 and the last version of register was updated in April 2011. The register includes all published and unpublished references to randomized, quasi-randomized and controlled clinical trials without language restrictions. The register is maintained on Meerkat 1.6. The Cochrane Schizophrenia Group\'s register contains 16,000 citations to 13,000 studies relating only to people with schizophrenia or schizophrenia-like illness <http://szg.cochrane.org/cochrane-schizophrenia-group-specialised-register>. These studies are reliably indexed regarding the country of origin, the interventions under study, and the number of participants.

Types of studies
----------------

We included all randomized controlled trials and controlled clinical trials undertaken in Italy. Studies were included if any pharmacological treatment was compared with other active pharmacological treatments or placebo. Only studies that enrolled patients in Italy were considered. Multicenter studies were included if all centers enrolling patients were located in Italy.

Selection of trials and data extraction
---------------------------------------

From the Cochrane Schizophrenia Group Register we extracted all records corresponding to studies carried out in Italy. We examined all titles and abstracts, and obtained full texts if the word \'random\' or \'randomized\' or \'control\' or \'controlled\' was present in the title and/or abstract. MP read the full texts, determined whether they met inclusion criteria, and extracted the data. Data were extracted using an electronic spreadsheet. Considerable care was taken to exclude duplicate publications. In order to ensure consistency, CB and CEA carried out a reliability check on all data extracted by comparing the data abstracted in the electronic spreadsheet with the paper version of each study. In case of disagreement between reviewers this was resolved by discussion.

We considered the following variables: year of publication, geographic area (north, center, south of Italy), language of publication (English, Italian), pharmacological treatment (Antipsychotics according to the WHO Anatomical Therapeutic Chemical \[ATC\] classification system, other pharmacological treatments), sample size, weeks of follow-up, diagnostic criteria (standardized criteria such as DSM or ICD, implicit criteria such as clinical judgment, or unclear criteria), description of random allocation and blinding (using the Cochrane Collaboration \'Risk of BIAS\' tool criteria), number of outcome measures (number of different psychopathological dimensions analyzed, as indexed in the specialized register), and use of the CONSORT flow-diagram.

Data presentation
-----------------

We calculated simple percentages (%) with 95% confidence intervals (CI). To ascertain whether sample size, length of follow-up, and number of efficacy measures have increased in the last 45 years, we used a box plot diagram and a non-parametric test for trend (extension of the Wilcoxon rank-sum test). Spearman\'s rank correlation coefficients for all pairs of variables were additionally calculated using data in continuous format. STATA 11 was used to carry out the statistical analysis.

Results
=======

General characteristics
-----------------------

The original search identified 155 records of potentially eligible studies, 74 of which did not meet inclusion criteria (Figure [1](#F1){ref-type="fig"}). For the remaining 81 records full text was retrieved and data extracted. The characteristics of included studies are presented in Table [1](#T1){ref-type="table"}.

![**PRISMA flow diagram**.](1745-6215-13-35-1){#F1}

###### 

Characteristics of schizophrenia drug trials published in Italy from 1948 to 2009 (*n*= 81 studies)

                              (*n*)   \% (95% CI)
  --------------------------- ------- ------------------
  *Area of Italy*                     
  North                       42      51.8 (40.4-63.0)
  Center                      19      23.4 (14.7-34.1)
  South                       20      24.6 (15.7-35.5)
  *Year of publication\**             
  1948-1980                   20      25.3 (16.2-36.3)
  1981-1995                   36      45.5 (34.3-57.1)
  1996-2009                   23      29.1 (19.4-40.4)
  *Language of publication*           
  English                     58      71.6 (60.4-81.0)
  Italian                     23      28.4 (18.9-39.5)
  *Drug treatment*                    
  Antipsychotics              64      79.0 (68.5-87.2)
  Other drugs                 17      20.1 (12.7-31.4)
  *Diagnostic criteria*               
  Unclear                     3       3.7 (0.77-10.4)
  Standardized criteria       52      64.2 (52.7-74.5)
  Implicit criteria           26      32.1 (22.1-43.3)

\*Two unpublished studies not included

*CI*confidence interval.

Most studies (52% CI 40-63) were conducted in north Italy, the majority were published between 1981 and 1995 (46% CI 34-57), and 72% (CI 60-81) were in English. The majority of studies evaluated antipsychotic drugs (79%, CI 69-87), while a minority assessed the beneficial effect of other drug treatments. Most also used standardized diagnostic criteria for defining schizophrenia (64% CI 53-75), whereas 32% (CI 22-43) used implicit criteria and 4% (CI 1-10) do not specify any diagnostic criteria.

Methodological characteristics
------------------------------

Most trials were of short duration, with only 20 (24.6% CI 15.7-35.5) being of medium or long-term follow-up (13 weeks or more) (Table [2](#T2){ref-type="table"}). In 10 cases the length of follow-up was unclear. Duration does not increase over time (z for trend = -0.41, *P*= 0.685) (Figure [2](#F2){ref-type="fig"}). Spearman\'s rank correlation coefficient confirmed no association between year and length of follow-up (rho = -0.030; *P*= 0.814)

###### 

Main methodological characteristics of schizophrenia drug trials published in Italy from 1948 to 2009 (*n*= 81 studies)

                                  *n*   \% (95% CI)
  ------------------------------- ----- ------------------
  *Sample size*                         
  Min-20                          22    27.1 (17.8-38.1)
  21-40                           32    39.5 (28.8-50.9)
  40-max                          27    33.3 (23.2-44.6)
  *Length of follow-up (weeks)*         
  Unclear                         10    12.3 (6.08-21.5)
  2-4                             30    24.6 (15.7-35.5)
  5-12                            21    25.9 (16.8-36.8)
  13+                             20    24.6 (15.7-35.5)
  *Randomization*                       
  Randomized, no details          51    62.9 (51.5-73.4)
  Randomized with details         7     8.6 (3.54-16.9)
  Unclear                         23    28.4 (18.9-39.5)
  *Blinding*                            
  Single blind                    6     7.4 (2.76-15.4)
  Double blind                    47    58.0 (46.5-68.9)
  Unclear                         28    34.5 (24.3-45.9)
  *Outcome measures (n)*                
  1-5                             33    40.7 (29.9-52.2)
  6-15                            35    43.2 (32.2-54.6)
  16-60                           13    16.0 (8.83-25.8)
  *Patient flow diagram*                
  Yes                             2     2.4 (0.30-8.63)
  No                              79    97.6 (91.3-99.6)

*CI*confidence interval

![**Length of Italian schizophrenia drug Trials published between 1984 and 2009 (*n*= 81)**. The horizontal line represents the median, the box extends to cover the interquartile range and the vertical line extends to the extremes.](1745-6215-13-35-2){#F2}

Two-thirds of trials had less than 40 participants (67% CI 55-77); sample size only minimally increased over time (Figure [3](#F3){ref-type="fig"}), as shown by Spearman\'s rank correlation coefficient (rho = 0.259; *P*= 0.020) but not by test for trend (z for trend = 0.48, *P*= 0.628). While the use of standardized diagnostic criteria progressively increased, accounting for more that 70% of trials published after 1995 (17/23), the use of implicit criteria dropped, accounting for less than 20% of trials published after 1995 (4/23).

![**Number of the patients in Italian schizophrenia drug trials published between 1984 and 2009 (*n*= 81)**. The horizontal line represents the median, the box extends to cover the interquartile range and the vertical line extends to the extremes.](1745-6215-13-35-3){#F3}

Most trials were described as \'randomized\' even though only seven (9% CI 4-17) provided details about the methods of allocation (Table [2](#T2){ref-type="table"}). In 23 studies (28% CI 19-40) the allocation procedure was unclear. Single blind was adopted in six studies (7% CI 3-15), double blind was adopted in 47 studies (58% CI 47-69). For the remaining 28 studies (35% CI 24-46) it was unclear if blinding was used or not.

The number of outcomes measures ranged from 1 to 5 in 33 studies (41%, CI 30-52), from 6 to 15 in 35 trials (43%, CI 32-55) and from 16 to 60 in 13 studies (16% CI 9-26). Numbers of outcomes measures increases over time (z for trend = 3.32, *P*= 0.001) (Figure [4](#F4){ref-type="fig"}). Spearman\'s rank correlation coefficient confirmed the association between year and number of outcomes (rho = 0.436; *P*\< 0.001).

![**Number of outcome measures employed in Italian schizophrenia drug trials published between 1984 and 2009 (*n*= 81)**. The horizontal line represents the median, the box extends to cover the interquartile range and the vertical line extends to the extremes.](1745-6215-13-35-4){#F4}

The CONSORT statement was first published in 1996 \[[@B13]\]. Two of the 23 studies since that time reported a patient flow diagram (8% CI 1-28).

Discussion
==========

To our knowledge, this is the first survey investigating content and volume of trial activity in Italy. Although the majority of Italian schizophrenia trials were published in international journals, most failed to report basic methodological details such as, for example, information about the methods of random allocation, and its concealment from the study investigators, or how blinding was preserved. It is therefore difficult to ascertain which studies are associated with a low risk of bias. This compelling issue similarly applies to trial activity conducted in other countries. China, for example, a country which has progressively increased its production of randomized studies in the last 10 years, is still under scrutiny for some aspects of trial quality, including random allocation, blinding, and dropout reporting. This seems quite relevant in different areas of medicine \[[@B14]\], as well as in mental health \[[@B15]\]. Poor reporting in mental health is common, involves both high and low income countries \[[@B4]\], and leads to risk in interpreting results \[[@B16]\]. In most cases it is not possible to go beyond identifying studies that seem to be randomized trials. This further reinforces the need to develop tools to better describe and appraise the adequacy of the randomization process in a culturally sensitive manner. Clearly, random allocation is a scientific process and it should not differ across cultures, but its reporting should take into consideration the different meaning that the world random might have in different cultures.

The Consolidated Standard of Reporting Trial (CONSORT) statement \[[@B13],[@B17]\] facilitates complete and transparent reporting, aids critical appraisal and interpretation of results. This simple checklist for reporting has been widely adopted \[[@B18]\]. Good trial reporting is important not only for guiding clinicians towards correct decision-making, but also for regulatory agencies working on drug approval. Certainly, clinicians and regulatory authorities should require higher standards from clinical trial reports \[[@B19]\]. Researchers and editors no longer have an excuse for bad reporting.

In Italy, in this subspecialty, while sample size increased only minimally over time, patient selection criteria and outcome assessments have become much more sophisticated, as suggested by the increase in use of standardized diagnostic criteria and by the steadily increase in the number of outcome measures. Although this trend may have increased the internal validity of findings, it has nevertheless allowed study of only highly refined groups of people with schizophrenia. This increasing drift from real world practice makes it difficult to apply trial results to typical patients \[[@B20],[@B21]\]. Similarly, we observed that the number of outcome measures has increased during the last 45 years. This confusion of measuring suggests, at the very least, a lack of consensus on what is important. Another example, if one was needed, supporting the need for a set of core outcome measures in this area \[[@B22]\]. Also increasing numbers of measures inevitably enhanced the probability of detecting chance significant differences. Rarely had the trials addressed this issue in the statistical analysis or in the interpretation of findings.

Our survey has some limitations. First, we did not include international multicenter studies where Italy was one site, possibly losing studies with good sample sizes and potentially better reporting. Second, as our focus was drug trials only, we collected no data on content and volume of trial activity in other fields of schizophrenia treatment, including psychological treatments, psychosocial interventions, and organizational approaches. This limits the generalizability of our findings, as we do not know if the current standard of drug trials can be considered representative of the whole spectrum of trial activity. Finally, we focused our survey on some indicators only, while it would have been of interest to describe trial activity with respect to other aspects, such as for example setting, intention to treat versus per protocol analysis, dropout reporting, economic support, ethics committee approval, and consent \'rituals\'.

Conclusions
===========

The Italian tradition in the area of evaluating treatments for people with schizophrenia is not as strong as in other similar countries \[[@B5]\]. Perhaps Italy has relied too much on studies undertaken outside its borders. There is an opportunity to produce more, better, independent, and nationally and internationally clinically relevant trials.
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